Scilex Holding Company
HealthcareNASDAQ:SCLX · NASDAQ Capital Market
-$0.20 today
Vol 0.12M · Avg 0.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$33.9M of revenue converted into -$419.7M of net income for the selected period. Gross margin is 49.0% and net margin is -1124.7%, showing how much revenue survives after costs and taxes. EPS is $-38.87, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.3M -46.5% | $56.6M +21.1% | $46.7M +22.9% | $38.0M +21.4% | $31.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $15.2M -8.8% | $16.7M +6.4% | $15.7M +45.2% | $10.8M +197.1% | $3.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $15.0M -62.3% | $39.9M +28.5% | $31.1M +14.0% | $27.2M -1.6% | $27.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 49.7% -20.8pp | 70.5% +4.1pp | 66.5% -5.2pp | 71.6% -16.8pp | 88.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $20.7M +114.8% | $9.6M -24.4% | $12.7M +40.8% | $9.1M -1.6% | $9.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $266.6M +124.0% | $119.0M -0.5% | $119.6M +84.4% | $64.9M +28.3% | $50.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $287.3M +133.0% | $123.3M -9.7% | $136.5M +75.3% | $77.9M +22.6% | $63.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.6M +14.3% | $4.0M -2.4% | $4.1M -6.9% | $4.5M +17.8% | $3.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$357.9M -435.9% | -$66.8M +38.8% | -$109.1M -1072.8% | -$9.3M +87.2% | -$72.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -1183.2% -1065.1pp | -118.0% +115.4pp | -233.4% -209.0pp | -24.5% +208.2pp | -232.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$272.3M -226.5% | -$83.4M +20.9% | -$105.4M -108.2% | -$50.6M -41.3% | -$35.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -900.1% -752.7pp | -147.4% +78.2pp | -225.6% -92.4pp | -133.1% -18.7pp | -114.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $11.5M +483.7% | $2.0M +83.8% | $1.1M -88.9% | $9.6M -18.4% | $11.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$101.7M -1060.7% | $10.6M +219.1% | -$8.9M -132.6% | $27.3M +151.9% | -$52.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$374.0M -413.7% | -$72.8M +36.3% | -$114.3M -389.4% | -$23.4M +73.6% | -$88.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1236.3% -1107.7pp | -128.7% +115.9pp | -244.6% -183.1pp | -61.4% +220.9pp | -282.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $26.0K +2700.0% | -$1.0K -107.7% | $13.0K +225.0% | $4.0K -20.0% | $5.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$358.7M -392.7% | -$72.8M +36.3% | -$114.3M -389.3% | -$23.4M +73.6% | -$88.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1185.8% -1057.1pp | -128.7% +115.9pp | -244.6% -183.2pp | -61.4% +220.9pp | -282.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$36 -87.8% | -$19 +56.7% | -$45 -636.5% | -$6 +73.9% | -$23 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$36 -87.8% | -$19 +56.7% | -$45 -636.5% | -$6 +73.9% | -$23 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $11.0M +58.7% | $7.0M +86.7% | $3.7M -2.9% | $3.8M +1.0% | $3.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $11.0M +58.7% | $7.0M +86.7% | $3.7M -2.9% | $3.8M +1.0% | $3.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Seer, Inc.
NASDAQ:SEER
$94.57M
Citius Oncology, Inc.
NASDAQ:CTOR
$61.74M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Incannex Healthcare Limited
IXHL
$43.99M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SCLX generate?
Scilex Holding Company (SCLX) reported $30.25M of revenue in fiscal 2025.
Is SCLX profitable?
Scilex Holding Company (SCLX) reported -$358,734,000.00 of net income, with a net margin of -1185.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.